Skip to NavigationSkip to content


Takeda collaboration to optimise biopharmaceutical manufacturing announced

A 36-month joint project between Takeda’s manufacturing site in Vienna, the Research Center Pharmaceutical Engineering (RCPE), InSilicoTrials, and the University of Graz has been initiated to establish the mechanistic basis of the relationship between process parameters and the effect of the resulting stresses on the characteristics of protein-based drugs.

BD unveils plan for €165 million Spanish manufacturing plant

BD has announced plans to build a new €160 million manufacturing plant in Zaragoza, located in the Aragon region of Spain, which will produce drug delivery devices and employ up to 600 people.

Construction of the new plant, the fourth facility for BD in Spain, is set to begin late this year. The site will initially have a workforce of 150 people and encompass an area of ​​8,000m2, with an expectation of expansion to 600 people and an area of ​​30,000m2 by 2030.

Sandoz announces €150 million investment in antibiotic production

Sandoz, a division of Novartis, has announced plans to develop its European antibiotics manufacturing network by expanding the production capabilities of its Austrian and Spanish sites with a €150 million investment.

In a release, Sandoz confirmed that it will invest more than €100 million to introduce new manufacturing technology for the production of oral amoxicillin, an active pharmaceutical ingredient (API) for its leading penicillin product, in its site in Kundl, Austria.

Cascade Chemistry begins $14m manufacturing facility expansion

Image credit: Business Wire

Cascade Chemistry, a leading pharmaceutical contract development and manufacturing organisation, has initiated the $14 million construction of new facilities to increase the company’s capacity to manufacture APIs (active pharmaceutical ingredients) under cGMP (current Good Manufacturing Practices standards and procedures).

AstraZeneca and Samsung Biologics partner up in $330m manufacturing and supply deal

AstraZeneca has announced a new global manufacturing and supply partnership with Samsung Biologics, said to be worth a potential $330.8 million.

As part of the deal, Samsung will offer its South Korea-based Plant 3 manufacturing facility to support large-scale drug substance production in support of AZ’s biologics portfolio. The plant, based in Incheon, is the largest single biomanufacturing facility in the world since opening in 2018. 

Is Pharma doing enough on sustainability?

Published on 20/07/20 at 03:06pm

Adoption of sustainable practices in pharmaceutical operations is ticking along, but given the environmental and health risks if this is not implemented as a matter of urgency, is progress coming fast enough? Matt Fellows investigates what measures pharma firms are taking in line with current guidance.

Over half of all US/EU regulator warnings issued to Indian and Chinese manufacturers, report finds

Concerns have been raised concerning the integrity of the global supply chain after a report from The Pharmaceutical Journal revealed that over half of the total formal warnings issued by US and European regulatory bodies are directed at facilities based in India or China.

The data noted by the report show that, of the 75 warning letters published to manufacturers by the FDA’s Office of Manufacturing Quality between early 2018 and August 2019, 37 in total were sent to these two countries – 18 to China and 19 to India.

Diagnosing the drug supply: Exposing the bad practice of manufacturers in the developing world

Published on 22/07/19 at 10:25am

The world needs cheap generic drugs and Indian manufacturers offer a steady supply. However the quality of generics has been sacrificed in the pursuit of bottom level prices. Louis Goss talks to investigative journalist Katherine Eban as she discusses the realities of the generic drug industry today.

GSK opens new manufacturing plants in Singapore

British multinational GlaxoSmithKline has opened two new manufacturing plants in Singapore.

The UK firm has also expanded facilities at its Jurong site, as part of an effort to “accelerate the supply of new breakthrough medicines to patients globally.”

The $96 million investment will see GSK employ a process called ‘continuous manufacturing’ with the aim of reducing production time and thus enabling faster supply of medicines across the globe.

Contract manufacturing services industry set to grow at CAGR of 10.6% between 2017-2027

The biopharmaceutical contract manufacturing market is expected to grow at a compound annual growth rate (CAGR) of 10.6% between 2017 and 2027, according to a report from Future Market Insights (FMI).

While Europe will continue to be the main source market for biopharmaceutical contract manufacturing services, the North American market is expected to expand at a CAGR close to 10% as profit margins remain higher in Europe than in the United States.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches